7/102 sources · 2 publishersUpdated Oct 23, 12:45 UTC
Cantor Fitzgerald reiterates Overweight rating on Trulieve Cannabis with $15 price target
Cantor Fitzgerald kept its Overweight rating on Trulieve Cannabis and maintained a $15 price target. The analyst highlighted the company's scaled, vertically integrated medical operations and its organized, scalable platform. The firm noted the stock trades around $10.92 and cited recent Q2 2026 earnings of $0.11 EPS, with revenue of $271 million.
Why it matters
The unchanged rating and $15 target suggest analysts see further upside, which could influence investor demand for TRLV. The earnings beat and revenue miss provide mixed signals for short‑term performance.
Key facts
- 1Cantor Fitzgerald reiterated an Overweight rating on Trulieve Cannabis. investing.com
- 2The firm kept its price target at $15.00. investing.com
- 3Trulieve's stock was trading at $10.92. investing.com
- 4Q2 2026 adjusted earnings were $0.11 per share. investing.com
- 5Q2 2026 revenue was $271 million. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.